They have both been linked to increased melanin production and increased tanning of the skin [2, 3, 4, 5, 6, 7]
Compound synthesis and formulation The different GLP1-based multi-agonists employed in the study, including GLP1/E, GLP1/GIP dual agonist, and GLP1/GIP/glucagon triagonist, as well as the GLP1 mono-agonist, were synthesized, purified and characterized as extensively reported elsewhere 33,34,35,74
FulopTLarbiADupuisGLe PageAFrostEHCohenAAet alImmunosenescence and inflamm-aging as two sides of the same coin: friends or foes
A clinical trial at Northwestern University (NCT07207148) is currently investigating GLP-1 agonists specifically in MS patients, and results from randomised trials will be needed to establish whether these medications have genuine disease-modifying effects